Parkinson's Disease Research & Education Institute
We are an international charity dedicated to helping Parkinson's patients, supporting research into the best methods of treating Parkinson's, and helping provide to those institutions that continue the fight against Parkinson's.
Parkinson's Disease Research & Education Institute (PDREI) is dedicated to providing information and assistance to the general public concerning Parkinson's. In addition, we collect and distribute information and educate the public on nutrition, which have proven healing qualities, with emphasis placed on the treatment and prevention of Parkinson's.
Parkinson's Disease Research & Education Institute (PDREI) directs its efforts and resources towards supporting programs and hospitals that teach the public about complimentary therapies for treatment of Parkinson's disease and other degenerative diseases.
Letter from the President
Parkinson's Disease Research & Education Institute in a non-profit international organization dedicated to provide support and medical awareness and nutritious foods to other organizations, hospitals and people.
The past year has been one of growth and utilizing our resources to maximize our impact in providing funds for education, awareness and continued research in hopes of finding a cure for Parkinson's disease . Parkinson's Disease Research & Education Institute has been driven by the challenges of providing research grants, aid, and support to those who suffer from Parkinson's disease. It is our commitment to help provide information and assistance to the general public concerning Parkinson's disease and other chronic diseases.
Parkinson's Disease Research & Education Institute will stay true of empowering people with Parkinson's by providing them with the information they need to stay healthy.
Miriam C. Montano
President - PDREI
Pimavanserin (Nuplazid™)has been approved by the US Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The drug’s manufacturer, Acadia Pharmaceuticals Inc., announced the approval on April 29. Pimavanserin is the first drug indicated specifically to treat symptoms of psychosis in Parkinson’s.
Give your helping hand to those who need it
What is Parkinson’s Disease?
Parkinson's disease (PD) is a chronic and progressive movement disorder, meaning that symptoms continue and worsen over time. Nearly one million people in the US are living with Parkinson's disease. The cause is unknown, and although there is presently no cure, there are treatment options such as medication and surgery to manage its symptoms.
Parkinson’s involves the malfunction and death of vital nerve cells in the brain, called neurons. Parkinson's primarily affects neurons in an area of the brain called the substantia nigra. Some of these dying neurons produce dopamine, a chemical that sends messages to the part of the brain that controls movement and coordination. As PD progresses, the amount of dopamine produced in the brain decreases, leaving a person unable to control movement normally.
The specific group of symptoms that an individual experiences varies from person to person. Primary motor signs of Parkinson’s disease include the following.
1.tremor of the hands, arms, legs, jaw and face
2.bradykinesia or slowness of movement
3.rigidity or stiffness of the limbs and trunk
4.postural instability or impaired balance and coordination
Scientists are also exploring the idea that loss of cells in other areas of the brain and body contribute to Parkinson’s. For example, researchers have discovered that the hallmark sign of Parkinson’s disease — clumps of a protein alpha-synuclein, which are also called Lewy Bodies — are found not only in the mid-brain but also in the brain stem and the olfactory bulb.
These areas of the brain correlate to nonmotor functions such as sense of smell and sleep regulation. The presence of Lewy bodies in these areas could explain the nonmotor symptoms experienced by some people with PD before any motor sign of the disease appears. The intestines also have dopamine cells that degenerate in Parkinson’s, and this may be important in the gastrointestinal symptoms that are part of the disease. Read More....